CA-SCIENTIST.COM
14.2.2024 13:56:34 CET | Business Wire | Press release
Scientist.com, the pharma industry’s leading research marketplace, and PhenoVista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, have launched the biotech industry’s first digital eShop for exploring and purchasing phenotypic studies.
The digital storefront makes it easy for scientists to design complex research projects, get feedback from PhenoVista’s experts, determine pricing, and then purchase and manage projects. What previously could require hours of face-to-face meetings or video calls can now be accomplished online in much less time. The Shopify-like virtual store was created by Scientist.com and is designed to make it as easy to purchase complex assay services as it is to buy products and reagents.
“Today, almost half of the $240B spent annually on drug research is performed by companies like PhenoVista that offer highly technical and specialized custom assay services,” said Kevin Lustig, PhD, CEO and Founder at Scientist.com. “With the launch of PhenoVista’s online store, researchers get more immediate access to their services and expertise, allowing them to accelerate crucial experiments and benefit from the use of data-rich phenotypic studies.”
There are significant advantages offered by high-plex phenotypic studies across the entire R&D workflow as compared to conventional, low-plex in vitro assays.
“High-stakes decision making is at the heart of R&D, and uncertainty about targets, mechanisms of action, and whether to advance or abandon candidate compounds is the norm,” said James G. Evans, CEO and Founder of PhenoVista. “With expertise in high-content imaging-based phenotypic studies, we deliver the biological insights and high-quality data needed to inform and de-risk these decisions. We are excited to leverage the marketplace experience established by Scientist.com to create our virtual storefront and bring added convenience to researchers in the biotech industry.”
The virtual storefront can be accessed at https://store.phenovista.com/.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram.
About PhenoVista
Founded in 2014, PhenoVista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence. Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates. To learn more, visit our website www.phenovista.com or see us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214355636/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 10:30:00 CEST | Press release
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assetsThe partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territoriesThe partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizum
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 10:00:00 CEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
Telekom Srbija (Group) Is Building City-Scale Digital Infrastructure for EXPO 20271.10.2026 10:00:00 CEST | Press release
On a site that will function, in terms of capacity, as an entirely new urban district, with more than 46 kilometres of fibre-optic network, 35 radio sites, 5G Standalone and Wi-Fi 7, Telekom Srbija Group is presenting the digital ecosystem it is building for over 135 participating countries and four million expected visitors. Telekom Srbija sees EXPO 2027 as a platform for strengthening its global positioning and marketing its products and services. Telekom Srbija Group is building telecommunications infrastructure at the EXPO 2027 Belgrade site whose mobile segment is comparable in scale to that of an entire urban district. On a site that previously had no telecommunications infrastructure, more than 14 kilometres of telecommunications ducting and over 46 kilometres of high-capacity fibre-optic network have been delivered so far, together with 35 advanced radio access network sites. The digital ecosystem, based on 5G Standalone and Wi-Fi 7 technologies, is designed to provide reliable
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform1.10.2026 09:30:00 CEST | Press release
ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience to develop its enterprise-grade digital offering that automates these services. The technology has been live in production for years, bundled with ROYC's services with more than 20 fund managers operating drawdown and evergreen funds on the ROYC OS, distributing to over 50 banks and wealth managers. “We saw where legacy solutions were failing fund managers: spreadsheets and software assembled from separate tools bolted together over time, with no single record connecting a fund to its service providers and investors,” said Octavian Popescu, Co-Founder and CEO of ROYC Group. “We built ROYC OS the other way aroun
Eaton Strengthens European Manufacturing With Expanded Production Facility in Austria1.10.2026 09:00:00 CEST | Press release
Increased capacity supports growing demand from electrification and critical infrastructure marketsNew fully automated miniature circuit breaker production and expanded low-voltage systems assembly capacity in Schrems5,000 m² facility expansion combines advanced automation, digital integration and end-to-end product traceability Eaton will celebrate the expansion of its manufacturing facility in Schrems, Austria, on 1 October 2026. The expansion supports growing demand driven by electrification and digitalisation across Europe while increasing regional manufacturing capacity for electrical protection and power management solutions. Completed in less than ten months, the expansion combines fully automated production with advanced digital integration and end-to-end product traceability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001416101/en/ Eaton expanded manufacturing capacity in Europe for power management solutions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom